Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$15MCash on Hand
9.4mo Cash Runway
Follow BOLT by emailGet an email when BOLT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BOLT, unsubscribe in one click. Privacy
📣 What BOLT Says Is Next
second quarter of 2027 · “It is now in Phase 2 development in asthma, COPD and atopic dermatitis, with an additional study planned in eosinophilic esophagitis, and we expect patient proof-of-concept data across all four studies beginning in the second quarter of 2027.”
Company press release, Nov 12, 2026 · SEC filing
2H 2027 · “Recently disclosed PRA-216 Phase 1 data provided first clinical validation of PRA-216 and the proprietary INSPIRE multispecific antibody platform with the potential for at-home maintenance dosing every 8 to 12 weeks; a second wholly owned INSPIRE program is expected to enter the clinic and generate initial clinical data in 2H 2027”
Company press release, Nov 12, 2026 · SEC filing
2Q 2027 · “Initiated Phase 2 studies with PRA-216, a half-life-extended IL-4Rα/TSLP bispecific, in asthma, atopic dermatitis and chronic obstructive pulmonary disease with initial data expected in 2Q 2027”
Company press release, Nov 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 12, 2026 ·
Earnings Reported Q3 2026 results: collaboration revenue was zero versus $2.2 million a year earlier, R&D expenses were $2.2 million versus $6.5 million, and G&A was $2.5 million versus $3.3 million. Form 8-K · SEC filing · Press release
Oct 23, 2026 ·
Deal Bolt acquired Prana Therapies via stock-for-stock merger, issuing 430,746 common shares and 16,360.929 Series D preferred shares. Concurrent $120 million private placement at $8,574.30 per Series D share, plus up to $60 million from warrants, expected to fund operations into 2028. Form 8-K · SEC filing · Press release
Oct 6, 2026 ·
Restructuring Bolt amended its Redwood City lease, paying the landlord $1.0 million and letting it draw the full $1.5 million letter of credit. The lease now expires December 31, 2027, or earlier after a financing or strategic deal, which triggers a $4.5 million termination payment. Form 8-K · SEC filing
Aug 11, 2026 ·
Earnings Reported Q2 2026 collaboration revenue of $5,000 versus $1.8 million a year earlier, R&D expenses of $5.1 million and G&A of $2.4 million, and a loss from operations of $8.4 million. Cash of $18.1 million is expected to fund operations into 1Q 2027. Initial BDC-4182 data is expected with 3Q 2026 results. Form 8-K · SEC filing · Press release
Aug 11, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
May 2027 · Phase 1/2 · Recruiting · A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not BOLT's own candidates): Nivolumab, Pertuzumab, Cemiplimab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
BOLT holds $15M in cash and short-term investments (as of Sep 30, 2026) and burns about $4.8M/quarter from operations,
an estimated runway of 9.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:49 · Elevated
Cash runway 9 months +30
Going-concern doubt in the latest 10-Q +15The Company has concluded that substantial doubt exists about its ability to continue as a going concern.10-Q, Nov 2026
Share count +36% in a year +14
Raised after last reported balance sheet (Oct 2026) -10
Share count 2,607,490 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full BOLT picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BOLT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.